[F:1][C:2]([F:14])([F:13])[C:3]1[CH:8]=[CH:7][CH:6]=[CH:5][C:4]=1[CH2:9][C:10]([OH:12])=O.[NH:15]1[CH2:20][CH2:19][C:18]2([C:28]3[C:23](=[CH:24][CH:25]=[CH:26][CH:27]=3)[NH:22][C:21]2=[O:29])[CH2:17][CH2:16]1>>[F:13][C:2]([F:1])([F:14])[C:3]1[CH:8]=[CH:7][CH:6]=[CH:5][C:4]=1[CH2:9][C:10]([N:15]1[CH2:20][CH2:19][C:18]2([C:28]3[C:23](=[CH:24][CH:25]=[CH:26][CH:27]=3)[NH:22][C:21]2=[O:29])[CH2:17][CH2:16]1)=[O:12]The title compound was prepared following a procedure analogous to that described in Example 31 using 2-(2-(trifluoromethyl)phenyl)acetic acid and spiro[indoline-3,4′-piperidin]-2-one. LC-MS Method 3 tR=1.089, min, m/z=389; NMR (CDCl3) 1.19 (m, 1H), 1.28 (m, 1H), 1.75 (m, 4H), 3.62 (m, 1H), 3.88 (m, 5H), 6.81 (d, 2H), 6.93 (m, 1H), 7.13 (m, 2H), 7.35 (m, 2H), 7.47 (m, 1H), 7.61 (d, 1H), 8.41 (s, 1H)